The new face of bispecific antibodies: Targeting cancer and much more

Experimental Hematology

Volumn 34, Issue 1, 2006, Pages 1-6

  Lum, Lawrence G ^a,b,c,d   Davol, Pamela A ^a,b   Lee, Randall J ^e  

^a Adele R Decof Cancer Center   (United States)

^b ROGER WILLIAMS MEDICAL CENTER   (United States)

^c BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d BROWN UNIVERSITY   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPECIFIC ANTIBODY; MONOCLONAL ANTIBODY;

ANTIBODY SPECIFICITY; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; CANCER IMMUNOTHERAPY; CELLULAR IMMUNITY; CLINICAL TRIAL; CYTOTOXIC T LYMPHOCYTE; EFFECTOR CELL; HEART FUNCTION; HEART INFARCTION; HEART MUSCLE INJURY; HEMATOPOIETIC STEM CELL; HOST CELL; HUMAN; HUMORAL IMMUNITY; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; POLYCLONAL ACTIVATION; PRIORITY JOURNAL; PROTEIN TARGETING; REVIEW; STEM CELL TRANSPLANTATION; TUMOR CELL DESTRUCTION;

ANTIBODIES, BISPECIFIC; ANTIGENS, CD34; CLINICAL TRIALS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; MYOCARDIAL INFARCTION; NEOPLASMS; T-LYMPHOCYTES;

EID: 30344457881     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exphem.2005.07.013     Document Type: Review

References (70)

1. A. Ullrich, and J. Schlessinger Signal transduction by receptors with tyrosine kinase activity Cell 61 1990 203 212
2. M. Balzar, M.J. Winter, C.J. de Boer, and S.V. Litvinov The biology of the 17-1A antigen (Ep-CAM) J Mol Med 77 1999 699 712
3. D.R. Negri, E. Tosi, and O. Valota In vitro and in vivo stability and anti-tumour efficacy of an anti-EGFR/anti-CD3 F(ab′)2 bispecific monoclonal antibody Br J Cancer 72 1995 928 933
4. T. Karashima, P. Sweeney, and J.W. Slaton Inhibition of angiogenesis by the antiepidermal growth factor receptor antibody ImClone C225 in androgen-independent prostate cancer growing orthotopically in nude mice Clin Cancer Res 8 2002 1253 1264
5. S. Canevari, D. Mezzanzanica, and A. Mazzoni Bispecific antibody targeted T cell therapy of ovarian cancer: clinical results and future directions J Hematother 4 1995 423 427
6. S.A. Rosenberg, P. Spiess, and R. Lafreniere A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes Science 233 1986 1318 1321
7. S.A. Rosenberg, B.S. Packard, and P.M. Aebersold Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report N Engl J Med 319 1988 1676 1680
8. M.E. Dudley, J.R. Wunderlich, and P.F. Robbins Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes Science 298 2002 850 854
9. Z. Liu, B. Savoldo, and H. Huls Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the prevention and treatment of EBV-associated post-transplant lymphomas Recent Results Cancer Res 159 2002 123 133
10. G.C. de Gast, A.A. van Houten, and I.A. Haagen Clinical experience with CD3 x CD19 bispecific antibodies in patients with B cell malignancies J Hematother 4 1995 433 437
11. C. Renner, G. Held, and S. Ohnesorge Role of perforin, granzymes and the proliferative state of the target cells in apoptosis and necrosis mediated by bispecific-antibody-activated cytotoxic T cells Cancer Immunol Immunother 44 1997 70 76
12. L.G. Lum, and P.A. Davol Retargeting T cells and Immune Effector Cells with Bispecific Antibodies G. Giaccone R. Schilsky P. Sondel Cancer Chemotherapy and Biological Response Modifiers, Annual 22 2005 Elsevier Health Sciences, UK 273 291
13. V. Raso, and T. Griffin Hybrid antibody with dual specificity for the delivery of ricin to immunoglobin bearing target cells Cancer Res 41 1981 2073 2078
14. J.A. Titus, P. Perez, A. Kaubisch, M.A. Garrido, and D.M. Segal Human K/natural killer cells targeted with hetero-cross-linked antibodies specifically lyse tumor cells in vitro and prevent tumor growth in vivo J Immunol 139 1987 3153 3158
15. P. Perez, J.A. Titus, and M.T. Lotze Specific lysis of human tumor cells by T cells coated with anti-T3 cross-linked to anti-tumor antibody J Immunol 137 1986 2069 2072
16. D.M. Segal, M.A. Garrido, and P. Perez Targeted cytotoxic cells as a novel form of cancer immunotherapy Mol Immunol 25 1988 1099 1103
17. L.G. Lum, R. Rathore, and F. Cummings Phase I/II study of treatment of stage IV breast cancer with OKT3 x trastuzumab-armed activated T cells Clin Breast Cancer 4 2003 212 217
18. P.A. Davol, J.A. Smith, N. Kouttab, G.J. Elfenbein, and L. Lum Anti-CD3 x Anti-HER2 bispecific antibody effectively redirects armed T cells to inhibit tumor development and growth in hormone-refractory prostate cancer-bearing SCID-Beige mice Clin Prostate Cancer 3 2004 112 121
19. H.E. Lum, M. Miller, and P.A. Davol Preclinical studies comparing different bispecific antibodies for redirecting T cell cytotoxicity to extracellular antigens on prostate carcinomas Anticancer Res 25 1A 2005 43 52
20. J.M. Gall, P.A. Davol, R.C. Grabert, M. Deavers, and L.G. Lum T cells armed with anti-CD3 x anti-CD20 bispecific antibody enhance killing of CD20+ malignant B-cells and bypass complement-mediated Rituximab-resistance in vitro Exp Hematol 33 2005 452 459
21. U. Reusch, M. Sundaram, P.A. Davol, S.D. Olson, J.B. Davis, K. Demel, J. Nissim, R. Rathore, P.Y. Liu, and L.G. Lum Anti-CD3 x anti-EGFR bispecific antibody redirects T cell cytolytic activity to EGFR-positive cancers in vitro and in an animal model Clin Cancer Res 12 2006 183 190
22. J.P. Uberti, I. Joshi, and M. Ueda Preclinical studies using immobilized OKT3 to activate human T cells for adoptive immunotherapy: optimal conditions for the proliferation and induction of non-MHC restricted cytotoxicity Clin Immunol Immunopathol 70 1994 234 240
23. M. Ueda, I.D. Joshi, and M. Dan Preclinical studies for adoptive immunotherapy in bone marrow transplantation: II. Generation of anti-CD3 activated cytotoxic T cells from normal donors and autologous bone marrow transplant candidates Transplantation 56 1993 351 356
24. M. Sen, D.M. Wankowski, and N.K. Garlie Use of anti-CD3 x anti-HER2/neu bispecific antibody for redirecting cytotoxicity of activated T cells toward HER2/neu Tumors J Hematother Stem Cell Res 10 2001 247 260
25. P.A. Davol, J.M. Gall, and R.C. Grabert Infusions of T cells armed with anti-CD3 x anti-her2/neu bispecific antibody modulate in vivo patient immune responses in phase I clinical trials for breast and hormone refractory prostate cancers [abstract] Blood 104 2004 379a
26. R.C. Grabert, J. Smith, J. Tiggs, N. Kouttab, and L.G. Lum Anti-CD3 Activated T cells armed with OKT3 x herceptin bispecific antibody, survive and divide, and secrete cytokines and chemokines after multiple cycles of killing directed at Her2/neu+ tumor targets [abstract] Proc Am Assoc Cancer Res 2003 656
27. I. Monleon, M.J. Martinez-Lorenzo, and L. Monteagudo Differential secretion of Fas ligand- or APO2 ligand/TNF-related apoptosis-inducing ligand-carrying microvesicles during activation-induced death of human T cells J Immunol 167 2001 6736 6744
28. C. Lenfant Fixing the failing heart Circulation 95 1997 771 772
29. American Heart Association 2001 Heart and Stroke Statistical Update 2001 American Heart Association
30. C. Lenfant Cardiovascular research: an NIH perspective Cardiovasc Surg 5 1997 4 5
31. J.N. Cohn, M.R. Bristow, and K.R. Chien Report of the National Heart, Lung, and Blood Institute Special Emphasis Panel on Heart Failure Research Circulation 95 1997 766 770
32. R.M. el Oakley, N.A. Yonan, B.M. Simpson, and A.K. Deiraniya Extended criteria for cardiac allograft donors: a consensus study J Heart Lung Transplant 15 1996 255 259
33. H.F. Tse, Y.L. Kwong, and J.K. Chan Angiogenesis in ischaemic myocardium by intramyocardial autologous bone marrow mononuclear cell implantation Lancet 361 2003 47 49
34. K.C. Wollert, G.P. Meyer, and J. Lotz Intracoronary autologous bone-marrow cell transfer after myocardial infarction: the BOOST randomised controlled clinical trial Lancet 364 2004 141 148
35. B.E. Strauer, M. Brehm, and T. Zeus Repair of infarcted myocardium by autologous intracoronary mononuclear bone marrow cell transplantation in humans Circulation 106 2002 1913 1918
36. H. Nagamine, G. Watanabe, and S. Shiobara Intramyocardial CD34+ cell transplantation combined with off-pump coronary artery bypass grafting Heart Surg Forum 7 2004 E285 E287
37. M. Reyes, A. Dudek, and B. Jahagirdar Origin of endothelial progenitors in human postnatal bone marrow J Clin Invest 109 2002 337 346
38. C. Stamm, B. Westphal, and H.D. Kleine Autologous bone-marrow stem-cell transplantation for myocardial regeneration Lancet 361 2003 45 46
39. P.C. Smits, R.J. van Geuns, and D. Poldermans Catheter-based intramyocardial injection of autologous skeletal myoblasts as a primary treatment of ischemic heart failure: clinical experience with six-month follow-up J Am Coll Cardiol 42 2003 2063 2069
40. J.D. Abbott, Y. Huang, and D. Liu Stromal cell-derived factor-1alpha plays a critical role in stem cell recruitment to the heart after myocardial infarction but is not sufficient to induce homing in the absence of injury Circulation 110 2004 3300 3305
41. T. Lapidot, and O. Kollet The essential roles of the chemokine SDF-1 and its receptor CXCR4 in human stem cell homing and repopulation of transplanted immune-deficient NOD/SCID and NOD/SCID/B2m(null) mice Leukemia 16 2002 1992 2003
42. C.E. Murry, M.H. Soonpaa, and H. Reinecke Haematopoietic stem cells do not transdifferentiate into cardiac myocytes in myocardial infarcts Nature 428 2004 664 668
43. L.B. Balsam, A.J. Wagers, and J.L. Christensen Haematopoietic stem cells adopt mature haematopoietic fates in ischaemic myocardium Nature 428 2004 668 673
44. J.M. Nygren, S. Jovinge, and M. Breitbach Bone marrow-derived hematopoietic cells generate cardiomyocytes at a low frequency through cell fusion, but not transdifferentiation Nat Med 10 2004 494 501
45. P. Menasche, A.A. Hagege, and J.T. Vilquin Autologous skeletal myoblast transplantation for severe postinfarction left ventricular dysfunction J Am Coll Cardiol 41 2003 1078 1083
46. E.C. Perin, H.F. Dohmann, and R. Borojevic Transendocardial, autologous bone marrow cell transplantation for severe, chronic ischemic heart failure Circulation 107 2003 2294 2302
47. S. Fuchs, L.F. Satler, and R. Kornowski Catheter-based autologous bone marrow myocardial injection in no-option patients with advanced coronary artery disease: a feasibility study J Am Coll Cardiol 41 2003 1721 1724
48. B. Sun, H. Fan, and T. Honda Activation of NF kappa B and expression of ICAM-1 in ischemic-reperfused canine myocardium J Mol Cell Cardiol 33 2001 109 119
49. H.K. Hawkins, M.L. Entman, and J.Y. Zhu Acute inflammatory reaction after myocardial ischemic injury and reperfusion. Development and use of a neutrophil-specific antibody Am J Pathol 148 1996 1957 1969
50. R.J. Gumina, P.J. Newman, D. Kenny, D.C. Warltier, and G.J. Gross The leukocyte cell adhesion cascade and its role in myocardial ischemia-reperfusion injury Basic Res Cardiol 92 1997 201 213
51. J.C. Hartman, D.C. Anderson, and A.L. Wiltse Protection of ischemic/reperfused canine myocardium by CL18/6, a monoclonal antibody to adhesion molecule ICAM-1 Cardiovasc Res 30 1995 47 54
52. T. Ishibashi, M. Kijima, and K. Yokoyama Expression of cytokine and adhesion molecule mRNA in atherectomy specimens from patients with coronary artery disease Jpn Circ J 63 1999 249 254
53. R. Kalawski, P. Bugajski, and J. Smielecki Soluble adhesion molecules in reperfusion during coronary bypass grafting Eur J Cardiothorac Surg 14 1998 290 295
54. X.L. Ma, A.S. Weyrich, and D.J. Lefer Monoclonal antibody to L-selectin attenuates neutrophil accumulation and protects ischemic reperfused cat myocardium Circulation 88 1993 649 658
55. M. Nagashima, T. Shin'oka, and G. Nollert Effects of a monoclonal antibody to P-selectin on recovery of neonatal lamb hearts after cold cardioplegic ischemia Circulation 98 1998 II391 II397
56. K. Jaakkola, S. Jalkanen, and K. Kaunismaki Vascular adhesion protein-1, intercellular adhesion molecule-1 and P- selectin mediate leukocyte binding to ischemic heart in humans J Am Coll Cardiol 36 2000 122 129
57. P.J. Simpson, R.F. Todd III, and J.C. Fantone Reduction of experimental canine myocardial reperfusion injury by a monoclonal antibody (anti-Mo1, anti-CD11b) that inhibits leukocyte adhesion J Clin Invest 81 1988 624 629
58. T. Aversano, W. Zhou, M. Nedelman, M. Nakada, and H. Weisman A chimeric IgG4 monoclonal antibody directed against CD18 reduces infarct size in a primate model of myocardial ischemia and reperfusion J Am Coll Cardiol 25 1995 781 788
59. B. Yang, D. Li, M.I. Phillips, P. Mehta, and J.L. Mehta Myocardial angiotensin II receptor expression and ischemia-reperfusion injury Vasc Med 3 1998 121 130
60. M.W. Irwin, S. Mak, and D.L. Mann Tissue expression and immunolocalization of tumor necrosis factor-alpha in postinfarction dysfunctional myocardium Circulation 99 1999 1492 1498
61. L.G. Lum, H. Fok, and R. Siever Targeting of Lin-Sca+ hematopoietic stem cells with bispecific antibodies to injured myocardium Blood Cells Mol Dis 32 2004 82 87
62. D. Lyn, X. Liu, N.A. Bennett, and N.L. Emmett Gene expression profile in mouse myocardium after ischemia Physiol Genom 2 2000 93 100
63. J. Mair, I. Wagner, and L. Fridrich Cardiac myosin light chain-1 release in acute myocardial infarction is associated with scintigraphic estimates of myocardial scar Clin Chim Acta 229 1994 153 159
64. K.L. Christman, A.J. Vardanian, and Q. Fang Injectable fibrin scaffold improves cell transplant survival, reduces infarct expansion, and induces neovasculature formation in ischemic myocardium J Am Coll Cardiol 44 2004 654 660
65. L.G. Lum, P.A. Davol, and R.E. Sievers Human stem cells armed with bispecific antibodies home to injury-specific molecules in myocardial infarcts in nude rats [abstract] Blood 104 2004 736a
66. L.G. Lum, J.F. Padbury, P.A. Davol, and R.J. Lee Virtual reality of stem cell transplantation to repair injured myocardium J Cell Biochem 95 2005 869 874
67. D. Orlic, J. Kajstura, and S. Chimenti Mobilized bone marrow cells repair the infarcted heart, improving function and survival Proc Natl Acad Sci U S A 98 2001 10344 10349
68. R. Lanza, M.A. Moore, and T. Wakayama Regeneration of the infarcted heart with stem cells derived by nuclear transplantation Circ Res 94 2004 820 827
69. S. Zhang, D. Wang, and Z. Estrov Both cell fusion and transdifferentiation account for the transformation of human peripheral blood CD34-positive cells into cardiomyocytes in vivo Circulation 110 2004 3803 3807
70. J. Kajstura, M. Rota, and B. Whang Bone marrow cells differentiate in cardiac cell lineages after infarction independently of cell fusion Circ Res 96 2005 127 137